VEXAS patients exhibit distinct clinical features, including a higher prevalence of specific somatic mutations (DNMT3A, TET2), unique bone marrow characteristics, and a generally lower risk of MDS progression. This evidence concerns the gene TET2 and myelodysplastic syndrome.